Trillium Therapeutics Stock Forecast, Price & News

-0.17 (-2.49 %)
(As of 07/29/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume622,057 shs
Average Volume1.33 million shs
Market Capitalization$696.71 million
P/E Ratio39.12
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive TRIL News and Ratings via Email

Sign-up to receive the latest news and ratings for Trillium Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Trillium Therapeutics logo

About Trillium Therapeutics

Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Mississauga, Canada.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.90 out of 5 stars

Medical Sector

397th out of 2,214 stocks

Pharmaceutical Preparations Industry

202nd out of 869 stocks

Analyst Opinion: 3.5Community Rank: 3.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Trillium Therapeutics (NASDAQ:TRIL) Frequently Asked Questions

Is Trillium Therapeutics a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Trillium Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Trillium Therapeutics stock.
View analyst ratings for Trillium Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Trillium Therapeutics?

Wall Street analysts have given Trillium Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Trillium Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Trillium Therapeutics?

Trillium Therapeutics saw a decline in short interest in the month of July. As of July 15th, there was short interest totaling 7,870,000 shares, a decline of 45.0% from the June 30th total of 14,320,000 shares. Based on an average trading volume of 1,380,000 shares, the days-to-cover ratio is currently 5.7 days. Approximately 9.7% of the company's stock are sold short.
View Trillium Therapeutics' Short Interest

When is Trillium Therapeutics' next earnings date?

Trillium Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for Trillium Therapeutics

How were Trillium Therapeutics' earnings last quarter?

Trillium Therapeutics Inc. (NASDAQ:TRIL) posted its quarterly earnings data on Friday, May, 7th. The biotechnology company reported ($0.11) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.17) by $0.06.
View Trillium Therapeutics' earnings history

How has Trillium Therapeutics' stock price been impacted by Coronavirus?

Trillium Therapeutics' stock was trading at $5.19 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TRIL stock has increased by 28.1% and is now trading at $6.65.
View which stocks have been most impacted by COVID-19

What price target have analysts set for TRIL?

7 brokers have issued twelve-month price objectives for Trillium Therapeutics' stock. Their forecasts range from $14.00 to $28.00. On average, they expect Trillium Therapeutics' share price to reach $21.83 in the next twelve months. This suggests a possible upside of 228.3% from the stock's current price.
View analysts' price targets for Trillium Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Trillium Therapeutics' key executives?

Trillium Therapeutics' management team includes the following people:
  • Dr. Jan Skvarka, Pres, CEO & Director (Age 54, Pay $812.5k)
  • Mr. James T. Parsons MAcc, CPA-CA, Chief Financial Officer (Age 56, Pay $543.38k)
  • Dr. Robert Uger, Chief Scientific Officer (Age 50, Pay $595.73k)
  • Dr. Penka Petrova, Chief Devel. Officer (Age 53, Pay $553.53k)
  • Dr. Ingmar Bruns M.D., Ph.D., Chief Medical Officer (Age 46, Pay $230k)
  • Benjamin Looker, Gen. Counsel
  • Dr. Rosemary Harrison, Sr. VP of Corp. Devel. & Strategy (Age 38)
  • Dr. Michael G. Hill, Head of Calgary Site
  • Ms. Kathleen Large, Sr. VP - Clinical Operations (Age 61)

Who are some of Trillium Therapeutics' key competitors?

What other stocks do shareholders of Trillium Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trillium Therapeutics investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Energy Transfer (ET), Gilead Sciences (GILD), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Actinium Pharmaceuticals (ATNM) and Evoke Pharma (EVOK).

What is Trillium Therapeutics' stock symbol?

Trillium Therapeutics trades on the NASDAQ under the ticker symbol "TRIL."

How do I buy shares of Trillium Therapeutics?

Shares of TRIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Trillium Therapeutics' stock price today?

One share of TRIL stock can currently be purchased for approximately $6.65.

How much money does Trillium Therapeutics make?

Trillium Therapeutics has a market capitalization of $696.71 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-59,350,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis.

How many employees does Trillium Therapeutics have?

Trillium Therapeutics employs 33 workers across the globe.

What is Trillium Therapeutics' official website?

The official website for Trillium Therapeutics is

Where are Trillium Therapeutics' headquarters?

Trillium Therapeutics is headquartered at 2488 DUNWIN DRIVE, MISSISSAUGA A6, L5L 1J9.

How can I contact Trillium Therapeutics?

Trillium Therapeutics' mailing address is 2488 DUNWIN DRIVE, MISSISSAUGA A6, L5L 1J9. The biotechnology company can be reached via phone at (416) 595-0627 or via email at [email protected]

This page was last updated on 7/30/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.